Oxford Immune Algorithmics
Oxford Immune Algorithmics (OIA) is an AI research, data, and product company focused on developing Artificial Super Intelligence for meaningful purposes. Spun out from King's College London with ties to Oxford and Cambridge, OIA leverages its deep AI expertise, including contributions to Siri, Alexa, and OpenAI's RAG system, to create predictive health solutions. Their flagship product, Algocyte®, is an end-to-end, scalable Health-as-a-Service (HaaS) solution for health monitoring. Algocyte® utilizes a minimally invasive, portable blood testing device (Algocyte® Mobile Health Station) and a cloud platform to collect, analyze, and predict health trends based on lifelong clinical data. The platform uses proprietary AI, including the Algocyte® Index and AlgocyteGPT®, to provide quantitative risk assessments, early detection of diseases, and personalized healthcare. OIA's approach is based on 'Algorithmic Probability' and causal diagnostics, aiming to solve critical human health challenges like disease burden, inequality in healthcare, and staff shortages. The company has been recognized with multiple innovation and AI prizes, and is ISO 13485 and ISO 27001 certified.
Oxford Immune Algorithmics
Oxford Immune Algorithmics (OIA) is an AI research, data, and product company focused on developing Artificial Super Intelligence for meaningful purposes. Spun out from King's College London with ties to Oxford and Cambridge, OIA leverages its deep AI expertise, including contributions to Siri, Alexa, and OpenAI's RAG system, to create predictive health solutions. Their flagship product, Algocyte®, is an end-to-end, scalable Health-as-a-Service (HaaS) solution for health monitoring. Algocyte® utilizes a minimally invasive, portable blood testing device (Algocyte® Mobile Health Station) and a cloud platform to collect, analyze, and predict health trends based on lifelong clinical data. The platform uses proprietary AI, including the Algocyte® Index and AlgocyteGPT®, to provide quantitative risk assessments, early detection of diseases, and personalized healthcare. OIA's approach is based on 'Algorithmic Probability' and causal diagnostics, aiming to solve critical human health challenges like disease burden, inequality in healthcare, and staff shortages. The company has been recognized with multiple innovation and AI prizes, and is ISO 13485 and ISO 27001 certified.
TL;DR
Core focus: AI-driven precision diagnostics and predictive/preventive healthcare (Algocyte platform)
Flagship product: Algocyte Mobile Health Station — portable blood analyser plus cloud platform
Certifications: ISO 13485 (medical device QMS) and ISO/IEC 27001:2022 (information security)
Recent disclosed funding: £5.1m seed round led by Medtech AI Ltd (Apr 6, 2021); SFC Capital participated
Dr. Hector Zenil (founder); Crunchbase additionally lists Jurgen Riedel as a founder